Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Brief description of study

If you have been diagnosed with colon cancer that was surgically removed but has spread to lymph nodes and is known as stage III colon cancer and your colon cancer is found to have deficient DNA mismatch repair, you may be eligible to participate in this study. The main goal of this study is to see if the addition of immune therapy drug atezolizumab to usual FOLFOX chemotherapy can improve your outcome compared to FOLFOX alone.

Clinical Study Identifier: s18-00111
ClinicalTrials.gov Identifier: NCT02912559

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.